The Serum Institute of India (SII) has applied for market authorization for its COVID-19 vaccine, Covovax, which is intended to be given as a booster dose to anyone 18 years of age and older who have already received two doses of Covishield or Covaxin.
On October 17, Prakash Kumar Singh, director of government and regulatory affairs at SII, informed the DCGI that the market authorization application for the heterologous booster dose of Covovax had been submitted.
Covovax is produced using technology that was transferred from Novavax. It has received conditional marketing authorization from the European Medicines Agency.
This news is written by Ms. Amrita Singh, Research Assistant, All India Legal Forum.